Guilland J-C, Favier A, Potier de Courcy G, Galan P, Hercberg S
Laboratoire de physiologie, UFR de médecine, BP 87900, 21079 cedex, Dijon, France.
Pathol Biol (Paris). 2003 Mar;51(2):111-21. doi: 10.1016/s0369-8114(03)00105-6.
Elevated plasma total homocysteine (tHcy) is considered as a risk factor for occlusive cardiovascular disease (CVD). This concept is based on the observations of premature vascular disease in patients with homocystinuria and on the association between tHcy and increased risk of CVD in prospective studies. However, some observations have raised questions about tHcy as a risk factor. First, low risk population based prospective studies tend to indicate a weak association or no association between tHcy and CVD. Second, several traditional risk factors for CVD are associated with tHcy and may confound the relation between tHcy and CVD. Third, the C667T transition of the methylenetetrahydrofolate reductase causes a moderate increase in tHcy but no or only minor increased CVD risk. Thus, only placebo-controlled intervention studies with tHcy-lowering B-vitamins and clinical endpoints can provide additional valid arguments for the debate over whether tHcy is a causal CVD risk factor.
血浆总同型半胱氨酸(tHcy)水平升高被视为闭塞性心血管疾病(CVD)的一个危险因素。这一概念基于对同型胱氨酸尿症患者过早发生血管疾病的观察,以及在前瞻性研究中tHcy与CVD风险增加之间的关联。然而,一些观察结果对tHcy作为一个危险因素提出了质疑。首先,基于低风险人群的前瞻性研究往往表明tHcy与CVD之间的关联较弱或无关联。其次,CVD的几个传统危险因素与tHcy相关,可能会混淆tHcy与CVD之间的关系。第三,亚甲基四氢叶酸还原酶的C667T转变会使tHcy适度升高,但不会增加CVD风险或只会使其轻微增加。因此,只有使用降低tHcy的B族维生素和临床终点进行的安慰剂对照干预研究,才能为关于tHcy是否是CVD因果危险因素的争论提供更多有效的论据。